Intervention Group - Ketorlac (NSAID) for Ureteral Stent Placement

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ureteral Stent Placement+1 MoreKetorolac Trometamol 30Mg/1mL Injection - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying whether the drug Ketorolac can help reduce symptoms related to stents.

Eligible Conditions
  • Ureteral Stent Placement
  • Kidney Stones

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 1 to 2 months post stent removal

Month 2
Analog Pain Scale, 0 - 10 rating of pain - Follow-up Visit
Stent insertion Day 1
Analog Pain Scale, 0 - 10 rating of pain - Stent insertion Day 1
Day 14
Analog Pain Scale, 0 - 10 rating of pain - Stent removal

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Intervention Group - Ketorlac (NSAID)
1 of 2
Placebo Group - Normal Saline
1 of 2

Active Control

Non-Treatment Group

36 Total Participants · 2 Treatment Groups

Primary Treatment: Intervention Group - Ketorlac (NSAID) · Has Placebo Group · Phase < 1

Intervention Group - Ketorlac (NSAID)
Drug
ActiveComparator Group · 1 Intervention: Ketorolac Trometamol 30Mg/1mL Injection · Intervention Types: Drug
Placebo Group - Normal Saline
Drug
PlaceboComparator Group · 1 Intervention: Normal saline · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 to 2 months post stent removal

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,803 Previous Clinical Trials
2,279,413 Total Patients Enrolled
Alana Desai, MDPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
5 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are 18 years of age or older and willing and able to provide informed consent.
References